Front page

Upcoming events

Navigating the current funding environment and other key challenges in drug development for 2024 and beyond

SwedenBIO office, Wallingatan 24, Stockholm.Partner event

From proposal to decision and implementation of new pharmaceutical legislation and the HTA Regulation

PharmaRelations head office, Frösundaviks Allé 1, SolnaExternal event

Hesa-Fredrik AW at Haymarket

Lobby bar, Hotel Haymarket, Hötorget, Stockholm, Sweden.SwedenBio event

Nordic Life Science Days

SwedenBIO annually organizes the largest partnering conference in the Nordic region – Nordic Life Science Days. Present your company to an international audience at home, participate in partnering meetings and take part in a packed stage program!

Swedish Pipeline Report

The Swedish Drug Discovery and Development Pipeline Report 2023 contains a mapping of drug development projects by companies headquartered in Sweden. Read it for a solid insight into the Swedish life science industry.

Business & Finance

How to create sustainable trading on the stock exchange

The life science sector is one of the strongest for listed small companies in Sweden. At the same time, the competition in the sector is fierce and it is necessary to work with the issues that affect share trading. A well-functioning share trading is important for creating growth in small and medium-sized companies.

Offer to you as an incubator company

Life for startup companies was not without challenges before the effects of the corona crisis hit, and the situation is now tough for many smaller companies. Now we want to contribute to building Sweden’s next generation of life science companies strong, for future export revenue and innovation power. Startup companies with up to four employees must be members of SwedenBIO for an annual fee of SEK 1,000.

What does the future look like for dual listings in the US? When is the right time? These are questions Adam Kostyal devotes himself to answering in the latest episode of Brännpunkt Life Science.

Brännpunkt Life Science is an interview series in collaboration with DNB Sweden that focuses the magnifying glass on the intersection between innovation, capital and health. In the first part, we meet Adam Kostyal, European head of listing at Nasdaq, who looks at how the stock market year looked for the sector, talks about the impact of the pandemic and shares his predictions for the future.

Fast facts from “The Swedish Drug Discovery and Development Pipeline 2023”

Companies headquartered in Sweden are currently researching new medicines.

Pharmaceutical projects underway, more than 100 in the field of cancer

Of the pharmaceutical companies are from academia or health care sector